Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. Capsida will receive a $ ...

Capsida Biotherapeutics yesterday revealed US pharma major AbbVie has exercised an option for the first neurodegenerative ...

Jan. 7, 2025 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration.

Parlay Finance, a SaaS-based Loan Intelligence System (LIS) for credit unions and community banks issuing SBA and small business loans, today announced the availability of its white paper, ...

AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32. The company has a market capitalization of $319.06 billion, a PE ratio of 62.69, a P/E/G ratio of 1.92 and a beta of 0.58.

CWA Asset Management Group LLC cut its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 13.1% in the 4th quarter, HoldingsChannel.com reports.The fund owned 48,383 shares of the company’s ...

In a regulatory filing, AbbVie (ABBV) stated, “Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense ...

Jan 6 (Reuters) - AbbVie (ABBV.N), opens new tab lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as ...